肿瘤坏死因子阻断与骨质疏松风险：回归未来
Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.
作者信息
Sambrook Philip
出版信息
Arthritis Res Ther. 2007;9(4):107. doi: 10.1186/ar2277.
Abstract
Osteoporosis is a common clinical problem, especially in patients with rheumatoid arthritis (RA). A reduction in bone mineral density (BMD) of the axial and appendicular skeleton ranging from 7% to 15% has been reported in RA in studies employing a variety of densitometric techniques. Reports consistent with a beneficial effect of tumour necrosis factor blockade on BMD have begun to emerge in recent years, and in Arthritis Research and Therapy, a case control study reports that patients treated with infliximab for RA had preservation of BMD in the lumbar spine and femoral neck compared to those treated with methotrexate.
摘要
骨质疏松症是一个常见的临床问题，在类风湿关节炎（RA）患者中尤为如此。采用多种骨密度测量技术的研究报告称，RA患者中轴骨和附属骨骼的骨矿物质密度（BMD）降低了7%至15%。近年来，关于肿瘤坏死因子阻断对骨密度有有益作用的报告开始出现，在《关节炎研究与治疗》杂志上，一项病例对照研究报告称，与接受甲氨蝶呤治疗的患者相比，接受英夫利昔单抗治疗的RA患者腰椎和股骨颈的骨密度得以保留。
相似文献
1
Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.肿瘤坏死因子阻断与骨质疏松风险：回归未来
Arthritis Res Ther. 2007;9(4):107. doi: 10.1186/ar2277.
2
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.类风湿关节炎患者接受阿达木单抗治疗1年后的骨密度：骨质流失停止。
Ann Rheum Dis. 2009 Mar;68(3):373-6. doi: 10.1136/ard.2008.091611. Epub 2008 Apr 13.
3
Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.低剂量甲氨蝶呤对类风湿关节炎患者骨密度的影响。
J Rheumatol. 1997 Aug;24(8):1489-94.
4
Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.抗肿瘤坏死因子治疗期间强直性脊柱炎患者骨密度增加：6 年随访研究。
J Rheumatol. 2013 Oct;40(10):1712-8. doi: 10.3899/jrheum.121417. Epub 2013 Aug 15.
5
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.使用抗TNF-α抗体治疗的类风湿关节炎患者骨矿物质密度增加：一项前瞻性开放标签试点研究。
Rheumatology (Oxford). 2005 Dec;44(12):1546-8. doi: 10.1093/rheumatology/kei082. Epub 2005 Nov 1.
6
Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study.TNF 抑制剂对接受双磷酸盐治疗的类风湿关节炎患者骨密度的影响：一项回顾性队列研究。
Rheumatol Int. 2020 Mar;40(3):481-487. doi: 10.1007/s00296-019-04418-1. Epub 2019 Aug 14.
7
8
Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy.肿瘤坏死因子α抑制对类风湿关节炎和脊柱关节炎患者骨密度及骨转换标志物的影响。
Semin Arthritis Rheum. 2009 Oct;39(2):116-22. doi: 10.1016/j.semarthrit.2008.04.004. Epub 2008 Jun 30.
9
Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.近期发病的活动性类风湿关节炎患者的骨密度变化
Ann Rheum Dis. 2008 Jun;67(6):823-8. doi: 10.1136/ard.2007.073817. Epub 2007 Jul 20.
10
The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis.低剂量改善病情抗风湿药物（DMARDs）对早期类风湿关节炎绝经前女性骨密度的影响
Med Arch. 2016 Apr;70(2):101-3. doi: 10.5455/medarh.2016.70.101-103. Epub 2016 Apr 1.
引用本文的文献
1
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.靶向治疗对风湿性和肌肉骨骼疾病骨骼的影响。
Nat Rev Rheumatol. 2022 May;18(5):249-257. doi: 10.1038/s41584-022-00764-w. Epub 2022 Mar 10.
2
Bone Mineral Density in Antiretroviral Therapy-Naïve HIV-1-Infected Young Adult -Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda.乌干达未接受抗逆转录病毒治疗的HIV-1感染年轻成年女性使用醋酸甲羟孕酮长效注射剂或非激素避孕药时的骨矿物质密度
JBMR Plus. 2020 Dec 21;5(2):e10446. doi: 10.1002/jbm4.10446. eCollection 2021 Feb.
3
Bone effects of biologic drugs in rheumatoid arthritis.生物药物对类风湿关节炎骨骼的影响。
Clin Dev Immunol. 2013;2013:945945. doi: 10.1155/2013/945945. Epub 2013 Jun 20.
4
Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.罗格列酮对合并脂肪萎缩的HIV感染患者骨骼的影响。
HIV Clin Trials. 2012 Jul-Aug;13(4):212-21. doi: 10.1310/hct1304-212.
5
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.抗逆转录病毒治疗起始时的骨转换、骨保护素/核因子κB受体活化因子配体及炎症反应：替诺福韦与非替诺福韦方案对比
Antivir Ther. 2011;16(7):1063-72. doi: 10.3851/IMP1874.
6
Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study.利妥昔单抗对类风湿关节炎患者骨重塑标志物的影响：一项前瞻性开放标签初步研究。
Rheumatol Int. 2011 Feb;31(2):269-72. doi: 10.1007/s00296-010-1560-9. Epub 2010 Jul 27.
7
Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.广泛性骨质流失作为近期发病的非洲裔美国类风湿关节炎患者三年影像学损伤的预测指标。
Arthritis Rheum. 2010 Aug;62(8):2219-26. doi: 10.1002/art.27510.
8
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.白细胞介素-6 在类风湿关节炎相关骨质疏松症中的作用。
Osteoporos Int. 2010 Aug;21(8):1287-93. doi: 10.1007/s00198-010-1192-7. Epub 2010 Mar 13.
9
Regulation of bone mineral density in morbidly obese women: a cross-sectional study in two cohorts before and after bypass surgery.病态肥胖女性骨密度的调节：一项针对两个队列在旁路手术前后的横断面研究。
Obes Surg. 2009 Mar;19(3):345-50. doi: 10.1007/s11695-008-9529-4. Epub 2008 Apr 29.
本文引用的文献
1
2
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.活动性类风湿关节炎患者在抗TNF-α治疗期间的骨代谢变化。
Ann N Y Acad Sci. 2006 Jun;1069:420-7. doi: 10.1196/annals.1351.040.
3
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.类风湿关节炎患者接受英夫利昔单抗治疗期间骨密度、骨代谢、骨保护素及核因子κB受体活化因子配体血清水平的评估
Ann Rheum Dis. 2006 Nov;65(11):1495-9. doi: 10.1136/ard.2005.044198. Epub 2006 Apr 10.
4
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.使用抗TNF-α抗体治疗的类风湿关节炎患者骨矿物质密度增加：一项前瞻性开放标签试点研究。
Rheumatology (Oxford). 2005 Dec;44(12):1546-8. doi: 10.1093/rheumatology/kei082. Epub 2005 Nov 1.
5
Osteoclast differentiation and activation.破骨细胞的分化与激活。
Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658.
6
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.核因子κB受体活化因子配体在介导绝经后早期女性骨吸收增加中的作用。
J Clin Invest. 2003 Apr;111(8):1221-30. doi: 10.1172/JCI17215.
7
A normative reference database study for Pronosco X-posure System.一项针对Pronosco X-posure系统的规范性参考数据库研究。
J Clin Densitom. 2001 Spring;4(1):5-12. doi: 10.1385/jcd:4:1:05.
8
Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications.炎症性关节炎中骨质流失的机制：诊断及治疗意义
Arthritis Res. 2000;2(1):33-7. doi: 10.1186/ar67. Epub 1999 Dec 22.
9
The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis?类风湿关节炎中的骨骼问题：骨侵蚀和骨质疏松的共同机制？
J Rheumatol. 2000 Nov;27(11):2541-2.
10
Osteoporosis in the rheumatoid hand--the effects of treatment with D-penicillamine and oral gold salts.类风湿性手部骨质疏松症——青霉胺和口服金盐治疗的效果
S Afr Med J. 1983 Jan 22;63(4):121-3.
Zotero 插件